Stay updated on T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The date on the webpage has been updated from March 20, 2025, to April 17, 2025.
    Difference
    0.7%
    Check dated 2025-04-23T15:57:47.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.
    Difference
    1.0%
    Check dated 2025-04-16T13:20:02.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.
    Difference
    0.7%
    Check dated 2025-04-09T05:57:54.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The date has been updated from February 19, 2025, to March 20, 2025.
    Difference
    0.7%
    Check dated 2025-03-25T13:38:10.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting certain services and products, as well as a specific date. Additionally, a new date has been added.
    Difference
    6%
    Check dated 2025-02-24T20:30:56.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    6%
    Check dated 2025-02-10T09:43:37.000Z thumbnail image

Stay in the know with updates to T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DXd and Immunotherapy in HER2+ NSCLC Clinical Trial page.